Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a randomized, open‐label, superiority, multicenter clinical trial for patientswith early or locally advanced (T≥2cm, N0‐3, M0) HER2‐positive breast cancer. It aims tocompare the efficacy of neoadjuvant treatment with 2 cycles of Pyrotinib + Trastuzumab +Docetaxel followed by 2 cycles of Pertuzumab + Trastuzumab + Docetaxel versus 4 cycles ofPertuzumab + Trastuzumab + Docetaxel. Exploratory analyses of ctDNA clearance rate andMRI response will also be conducted.
Epistemonikos ID: beae70b3c1b4f37ac2fc487217de841a58ba6891
First added on: Sep 01, 2026